Randi M Schuster1, Corinne Cather2, Gladys N Pachas1, Haiyue Zhang3, Kristina M Cieslak1, Susanne S Hoeppner1, David Schoenfeld4, A Eden Evins1. 1. Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, United States; Harvard Medical School, United States. 2. Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, United States; Harvard Medical School, United States. Electronic address: ccather@mgh.harvard.edu. 3. Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, United States; MGH Biostatistics Center, United States; Harvard T.H. Chan School of Public Health, United States. 4. Harvard Medical School, United States; MGH Biostatistics Center, United States; Harvard T.H. Chan School of Public Health, United States.
Abstract
BACKGROUND: The estimated mortality gap between those with and without serious mental illness (SMI) is increasing, now estimated at 28years, which is largely due to smoking-related diseases. AIMS: We sought to identify predictors of 14-day continuous abstinence in stable outpatient smokers with SMI. METHOD: Adult smokers with schizophrenia spectrum (n=130) or bipolar disorder (n=23) were enrolled in a 12-week course of varenicline and cognitive-behavioral therapy for smoking cessation. RESULTS: Independent predictors of abstinence included reduction in withdrawal symptoms prior to the quit day, fewer cigarettes smoked per day at baseline, better baseline attention, remitted alcohol dependence, and lower expectation of peer support to aid quitting. CONCLUSIONS: Interventions that consider these targets may improve smoking cessation outcomes in those with SMI.
BACKGROUND: The estimated mortality gap between those with and without serious mental illness (SMI) is increasing, now estimated at 28years, which is largely due to smoking-related diseases. AIMS: We sought to identify predictors of 14-day continuous abstinence in stable outpatient smokers with SMI. METHOD: Adult smokers with schizophrenia spectrum (n=130) or bipolar disorder (n=23) were enrolled in a 12-week course of varenicline and cognitive-behavioral therapy for smoking cessation. RESULTS: Independent predictors of abstinence included reduction in withdrawal symptoms prior to the quit day, fewer cigarettes smoked per day at baseline, better baseline attention, remitted alcohol dependence, and lower expectation of peer support to aid quitting. CONCLUSIONS: Interventions that consider these targets may improve smoking cessation outcomes in those with SMI.
Authors: A Eden Evins; Corinne Cather; Nancy A Rigotti; Oliver Freudenreich; David C Henderson; Casey M Olm-Shipman; Donald C Goff Journal: J Clin Psychiatry Date: 2004-03 Impact factor: 4.384
Authors: A Eden Evins; Corinne Cather; Thilo Deckersbach; Oliver Freudenreich; Melissa A Culhane; Casey M Olm-Shipman; David C Henderson; David A Schoenfeld; Donald C Goff; Nancy A Rigotti Journal: J Clin Psychopharmacol Date: 2005-06 Impact factor: 3.153
Authors: Donald C Goff; Corinne Cather; A Eden Evins; David C Henderson; Oliver Freudenreich; Paul M Copeland; Michael Bierer; Kenneth Duckworth; Frank M Sacks Journal: J Clin Psychiatry Date: 2005-02 Impact factor: 4.384
Authors: Sara L Dolan; Kristi A Sacco; Angelo Termine; Aisha A Seyal; Melissa M Dudas; Jennifer C Vessicchio; Bruce E Wexler; Tony P George Journal: Schizophr Res Date: 2004-10-01 Impact factor: 4.939
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: A Eden Evins; Neal L Benowitz; Robert West; Cristina Russ; Thomas McRae; David Lawrence; Alok Krishen; Lisa St Aubin; Melissa Culhane Maravic; Robert M Anthenelli Journal: J Clin Psychopharmacol Date: 2019 Mar/Apr Impact factor: 3.153
Authors: Mary F Brunette; Joelle C Ferron; Susan R McGurk; Jill M Williams; Amy Harrington; Timothy Devitt; Haiyi Xie Journal: JMIR Ment Health Date: 2020-02-08